Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05364073 · ClinicalTrials.gov registry record · Phase 1

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

A Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and Metastatic Non Small Cell Lung Cancer, sponsored by ArriVent BioPharma.

Active
Registry status
Phase 1
Development phase
160
Enrollment target
20
Study locations

NCT05364073 is a Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and Metastatic Non Small Cell Lung Cancer that is active but no longer recruiting, run by ArriVent BioPharma. The registered enrollment target is 160 participants, below the 286-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (44% lower). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05364073, a Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and Metastatic Non Small Cell Lung Cancer, is active but no longer recruiting, sponsored by ArriVent BioPharma.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
160 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 1b, open-label, multi-center, dose-escalation and dose expansion study designed to evaluate the safety, pharmacokinetics (PK), and preliminary antitumor activity of furmonertinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with activating, including uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) mutations. Patients will be enrolled into one of 2 stages: Stage 1 (Dose Escalation and Backfill Cohorts) and Stage 2 (Dose Expansion).

Conditions Studied

Non-small Cell Lung Cancer (NSCLC) Metastatic Non Small Cell Lung Cancer Advanced Non-Small-Cell Lung Cancer EGFR Exon 20 Mutations HER2 Exon 20 Mutations EGFR Uncommon Mutations, Including G719X and S768I

Interventions

  • DRUG Furmonertinib

Study Locations (20)

California

  • ArriVent Investigative Site - Sacramento
  • ArriVent Investigative Site - Whittier

New South Wales

  • ArriVent Investigative Site - Blacktown
  • ArriVent Investigative Site - St Leonards

Other

  • Arrivent Investigative Site - Edmonton
  • Arrivent Investigative Site - Toronto

Beijing Municipality

  • Allist Investigative Site - Beijing
  • Allist Investigative Site - Chaoyang

Henan

  • Allist Investigative Site - Zhengzhou
  • Allist Investigative Site - Zhengzhou

Arizona

  • ArriVent Investigative Site - Prescott

Florida

  • ArriVent Investigative Site - Celebration

Michigan

  • ArriVent Investigative Site - Detroit

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2022-06-30
Est. Completion 2026-12-31
Phase Phase 1

Sponsor

ArriVent BioPharma

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05364073

The ClinicalTrials.gov registry entry for NCT05364073 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 286-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (44% lower). The listed sponsor is ArriVent BioPharma, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Non-small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 1 intervention - of which Furmonertinib is the first listed.

NCT05364073 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, New South Wales, Other.

Frequently Asked Questions

What is clinical trial NCT05364073 about?

NCT05364073 is a clinical study titled "Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations". This is a Phase 1b, open-label, multi-center, dose-escalation and dose expansion study designed to evaluate the safety, pharmacokinetics (PK), and preliminary antitumor activity of furmonertinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with activating, including unc...

What is the current status of trial NCT05364073?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 160 participants. The study started on 2022-06-30. Estimated completion is 2026-12-31.

What conditions does trial NCT05364073 study?

This clinical trial studies the following conditions: Non-small Cell Lung Cancer (NSCLC), Metastatic Non Small Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR Exon 20 Mutations, HER2 Exon 20 Mutations.

What interventions are being tested in trial NCT05364073?

The interventions under investigation include: Furmonertinib (DRUG).

Who is sponsoring clinical trial NCT05364073?

This trial is sponsored by ArriVent BioPharma, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05364073 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-small Cell Lung Cancer (NSCLC)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-small Cell Lung Cancer (NSCLC)

All registered trials for this condition

Metastatic Non Small Cell Lung Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.